We prospectively compared the efficacy of anterior palatoplasty and the uvulopalatal flap procedure for the treatment of patients with mild and moderate obstructivesleep apnea syndrome (OSAS) 
Introduction
Obstructive sleep apnea syndrome (OSAS) is characterized by episodes of partial or complete obstruction of the upper airway during sleep, which results in interruptions (apnea) or reductions (hypopnea) of the flow of air; the transient awakening that follows leads to the restoration of upper airway permeability. 1 In the upper airway, the retropalatal area is the most common site of the obstructive process.v ' Since Fujita et al first described uvulopalatopharyngoplasty (UPPP) in 198I,4 many studies have been published about its efficacy and complication rates. Studies have shown that while short-term success rates ranged from 76 to 95%, rates after 1year fell to only 46 to 50%. [5] [6] [7] [8] [9] Since UPPP has been associated with high recurrence and complication rates and patient discomfort, other procedures have been introduced to restore the space at the retropalatal area. 9 ,10 One of them is the uvulopalatal flap procedure, which was first described by Powell et al in 1996.
11 Studies showed that flap placement yielded success rates similar to those of UPPP but with less postoperative pain.":" Nevertheless, postoperative pain is still a common complication of the uvulopalatal flap procedure, as is temporary velopharyngeal insufficiency and a permanent foreign-body sensation in the pharynx.P-" www.entjournal.com .69 ~__ ...~~._ _______ HAYToGLU, ARIKAN, MULUK,TUHANloGLU, CORTUK
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A modified cautery-assisted palatal stiffening procedure was introduced by Pang and Terris in 2007 as an alternative to the flap procedure." They subsequently called this procedure anterior palatoplasty. IS In their first study, which looked at a small series of patients with mild OSAS, they observed surgical success in 6 of 8 patients (75.0%) as determined by polysomnography, as well as a reduction in daytime sleepiness scores in 11 of 13 patients (84.6%).14 In a subsequent study of77 patients published in 2009, Pang et al found a success rate of71.8% for anterior palatoplasty with or without tonsillectomy at a mean of 33.5 months of follow-up." With anterior palatoplasty, temporary velopharyngeal insufficiency and postoperative pain are also common, but a foreign-body sensation is not.
In a 2013 study by Marzetti et al, success rates for. anterior palatoplasty and the uvulopalatal flap procedure were 86 and 84%, respectively." The authors reported lower pain scores in the palatoplasty group. In both groups, they performed a tonsillectomy first if the tonsil size was greater than grade 2. Previous studies of palatal surgeries in OSAS patients had not considered the possible effects of tonsillectomyon success rates and postoperative discomfort, especially pain.
In this article, we describe our comparison of the efficacy of anterior palatoplasty and the uvulopalatal flap procedure for the treatment of mild and moderate OSASin patients with retropalatal obstruction who did not require a tonsillectomy.
Patients and methods
For this prospective study, we recruited 50 patients who had been diagnosed with mild or moderate OSAS in the ENT Clinic at Adana Numune Training and Research Hospital from June 2012 through January 2014. All diagnoses had been based on the results of polysomnography. All patients had undergone a complete head and neck examination, including flexible fiberoptic nasopharyngoscopy to evaluate the posterior airway space. All were found to have retropalatal collapse, based on the Muller maneuver.
Our inclusion criteria were an apnea-hypopnea index (AHI) ofgreater than 5 and less than 30, a body mass index (BMI) of less than 30 kg/rrr', a tonsillar hypertrophy grade of 0 or 1,17 and the presence of retropalatal obstruction. Exclusion criteria included previous palatal surgery, the presence ofa retrolingual obstruction, and the presence of a chronic disease that prevented surgery.
Of the 50 patients, 25 were randomly assigned to undergo anterior palatoplasty and 25 were randomized to uvulopalatal flap surgery. Tonsillectomy was not performed in either group. During surgery, sutures became unraveled in 3 palatoplasty patients and 2 flap 70 -www.entjournal.com patients, and thus these cases were not included in our final analysis. As a result, our final study population was made up of 45 patients. The palatoplasty group included 22 patients-12 men and 10 women, aged 28 to 49 years (mean: 39.2)-and the flap group included 23 patients-14 men and 9 women, aged 28 to 56 years (mean: 41.3).
Surgical procedures. Anterior palatoplasty. All palatoplasties were performed with general anesthesia. First, the mucosa and submucosal tissue (including fat) were removed as a horizontal rectangular strip (70 to 100 mm long and 40 to 50 mm wide) from the lingual surface of the soft palate down to the muscle layer. Bipolar cautery was used for hemostasis. The remaining tissue was sutured with 4-0 Vicryl and a round-body curved needle.
Uvulopalatal flap procedure. All flap procedures were likewise performed with general anesthesia. After insertion of a Dingman mouth gag, the projection formed by folding the uvula toward the soft palate was determined and the mucosa, submucosa with glands, and the fat on the lingual surface of the uvula and soft palate according to the determined area were removed with a scalpel. Then the uvular tip was amputated. Once bleedingwas controlled, horizontal incisions were made to the upper part of the posterior plicas of the tonsils. The uvula was folded into its new position and was fixed with 3-0 Vicryl sutures.
During the postoperative period, patients were administered analgesia in the form of acetaminophen at 250 mg/5 ml in doses of 10 to 15 mg/kg per dose 4 times a day.IS Patients were permitted to take additional acetaminophen as long as the total daily dose did not exceed 4 g. All acetaminophen intake was recorded.
Data collection. In addition to demographic information, we compiled pre-and postoperative data on patients' AHI, snoring, sleep quality, daytime sleepiness, and postoperative pain. We also recorded the duration of surgery and the amount of intraoperative blood loss.
AHI. The primary outcomes measure was the difference between pre-and postoperative AHI at 6 months after surgery as determined by polysomnography. The other findings were secondary outcomes.
Snoring. Snoring was assessed by bed partners preoperatively and 6 months postoperatively with the use of a visual analog scale (VAS) of 0 (none) to 10 (extremely loud).
Quality ofsleep. We assessed the quality of sleep with the Pittsburgh SleepQuality Index (PSQI), which is one of the most commonly used scales in sleep research." It was originally designed for use in clinical populations as a simple and valid assessment of both sleep quality and sleep disturbance that might affect sleep quality. (-TOPICAL is available through all major wholesalers and LanneUDirect.com
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PRECAUTIONS
The safety and effectiveness of cocaine hydrochloride topical solution depends onproper dosage, correct technique, adequate precautions, and readiness for emergencies. Standard textbooks should be consulted for specific techniques and precautions for various anesthetic procedures.
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ADVERSE REACTIONS
Adverse reactions may be due to high plasma levels asa result of excessive and rapid absorption ofthe drug. Reactions are systemic in nature and involve the central nervous system and/or the cardiovascular system. Asmall number of reactions may result from hypersensitivity, idiosyncrasy or diminished tolerance onthe part ofthe patient.
CNS reactions are excitatory and/or depressant, and may be characterized by nervousness, restlessness and excitement. Tremors and eventually clonic-tonic convulsions may result. Emesis may occur. Central stimulation is followed by depression, with death resulting from respiratory failure.
Small doses of cocaine slow the heart rate, but after moderate doses, the rate is increased due to central sympathetic stimulation.
Cocaine is pyrogenic, augmenting heat production in stimulating muscular activity and causing vasoconstriction which decreases heat loss. Cocaine is known to interfere with the uptake of norepinephrine byadrenergic nerve terminals, producing sensitization to catecholamines, causing vasoconstriction and mydriasis.
Cocaine causes sloughing of the corneal epithelium, causing clouding, pitting, and occasionally ulceration of the cornea. The drug is notmeant for ophthalmic use.
OVERDOSAGE
The fatal dose of cocaine has been approximated at1.2g., although severe toxic effects have been reported from doses aslowas20mg.
Symptoms -The symptoms of cocaine poisoning are referable to the CNS, namely the patient becomes excited, restless, carrulcus, anxious and confused. Enhanced reflexes, headache, rapid pulse, irregular respiration, chills, rise in body temperature, mydriasis, exophthalmos, nausea, vomiting and abdominal pain are noticed. Insevere overdoses, delirium, Cheyne-Stokes respiration, convulsions, unconsciousness, and death from respiratory arrest result. Acute poisoning bycocaine is rapid in developing.
Treatment -The specific treatment of acute cocaine poisoning isthe intravenous administration of a short-acting barbiturate or diazepam. Artificial respiration may be necessary. It is important to limitabsorption of the drug. If entrance of the drug into circulation can be checked, and respiratory exchange maintained, the prognosis isfavorable since cocaine is eliminated fairly rapidly.
DOSAGE AND ADMINISTRATION
The dosage varies and depends upon the area to be anesthetized, vascularity of the tissues, individual tolerance, and the technique of anesthesia. The lowest dosage needed to provide effective anesthesia should be administered. Dosages should be reduced for children and for elderly and debilitated patients. Cocaine hydrochloride topical solution should be administered using cotton or rayon pledgets. The advantages of the PSQI include its ability to (1) discern patterns of sleep dysfunction over a stipulated period of 1 month by assessing qualitative as well as quantitative data and (2) allow for the calculation of a simple global score that can convey both the number and severity of sleep problems for use in both clinical practice and research.
The PSQI consists of 19individual items that produce seven component scores and a global sleep quality score. The seven components include sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbance, use ofsleeping medications, and daytime dysfunction. These components were chosen on the basis of the standard areas that are assessed by clinicians during routine examinations of sleep problems. The PSQI is based on variable response categories pertaining to a patient's usual bedtime, usual wake time, the number of hours actually slept, and the number of minutes that passed before falling asleep, as well as forced-choice Likert-type responses.
The total PSQI score can range from ato 21 BMI, duration of surgery, and blood loss. There were no statistically significant differences in BMI between the two groups and no significant differences within groups pre-and postoperatively. The mean duration of surgery was 29.1 minutes in the palatoplasty group and 32.9 minutes in the flap group (p = 0.057). The mean amount ofintraoperative blood loss in the two groups was 6.8 and 7.4 ml, respectively (p
=0.991) (table 1).
AHI. The mean AHI in the palatoplasty group improved significantly from 17.5 before surgery to 8.1 at 6 months postoperatively (p < 0.001). In the flap group, the AHI fell from 18.5 to 8.6 (p < 0.001).There were no Significant differences between the two groups either pre-or postoperatively (table 2) .
Based on the AHI, we determined that the surgical success rates were 81.8% in the palatoplasty group (18 of 22 patients) and 82.6% in the flap group (19 of 23 patients). We defined success as described by Sher et aP 2as a postoperative reduction of at least 50% in the AHI combined with a postoperative AHI of less than 10.
Snoring. The VAS score for snoring was 8.1 preoperatively and 3.0 postoperatively (p < 0.001) in the palatoplasty group and 8.6 and 2.8, respectively, in the flap group (p < 0.001). Again, the differences between groups were not significant (table 2) . Sleep quality. The PSQI score in the palatoplasty group was 5.9preoperativelyand 4.3 postoperatively (p < 0.001);in the flap group, the corresponding scores were 6.7 and 4.7 (p < 0.001).The differences between the two groups at both assessments were not significant (table 2) .
Daytime sleepiness. ESS values in the palatoplasty group improved from 13.6to 6.4 (p < 0.001), and in the flap group they improved from 10.8 to 5.4 (p < 0.001). The differences between the two groups were not significant (table 2) .
Postoperative pain. VAS scores for postoperative pain at rest were Significantly lower in the palatoplasty group than in the flap group at postoperative hours 2, 4, and 8 and on days 4 through 7 (p < 0.002). Scores in the palatoplasty group peaked throughout the first 24 hours after surgery. In the flap group, scores were likewise highest on the day of surgery, and they generally declined afterward ( figure 1) .
Likewise, scores for pain during swallowing were significantly lower in the palatoplasty group at 2, 4, 8, and 16th hours and on days 4 through 7 (p < 0.009). Scores in both groups generally declined after day 1 (figure 2).
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Other complications. No primaryor secondaryhemorrhage or velopharyngeal insufficiency was observed in any patient. In the flap group, 8 patients reported a continuing foreign-body sensation in the pharynx at 6 months postoperatively; only 1 patient in the palatoplasty group reported the same.
Discussion
The goal of surgery in OSAS patients is to create greater airway dimensions while causing minimal postoperative complications after the operation." One of the complications that surgeons wish to avoid is postoperative discomfort.
In our study, we found that anterior palatoplasty and the uvulopalatal flap procedure were equally efficacious in treating OSAS.There were no significant differences in outcomes between the two groups in terms of the duration of surgery, intraoperative blood loss, and postoperative AHI, snoring, sleep quality, and daytime sleepiness. Moreover, in both groups, the AHI, snoring, PSQI, and ESS values were all significantly lower at 6 months postoperatively than they were preoperatively. The only significant difference we observed between the two groups was that the degree of postoperative HAYToGLU, ARIKAN, MULUK, TUHANloGLU, <;bRTUK and daytime sleepiness before and 24 months after surgery, along with postoperative pain. They found that mean snor---Palalopla sly group ing VAS scores and ESS scores were significantly lower after surgery in both groups (p < 0.025 for both). Pain scores were significantly lower in the palatoplasty group (p < 0.001). Patient satisfaction scores were 85% in the palatoplasty group and 70%in the mUPPP group. Cekin et al compared UPPP and uvulopalatal flap placement in OSAS patients and found that snoring was relieved in 85% of the UPPP patients and 83.3% of the flap patients 90 days after surgery." The degree of postoperative pain was greater in the Ul'Pl' group, and the mean duration of pain was significantly longer. The authors concluded that the uvulopalatal flap procedure was preferable to UPPP.
Akcam et al compared the severity of pain occurring after different surgical procedures and sought to determine appropriate analgesic requirements for the first 24 hours postoperatively." In their study, patients underwent either anterior palatoplasty, lateral pharyngoplasty, or tongue base suspension suturing. Tramadol delivered by a patient-controlled analgesia device and, when necessary, rescue pethidine (meperidine in the United States) were used for pain relief.
Postoperative pain scores in the tongue base suspension group of the Akcam study were higher than those in the palatoplasty group at all time points except at hour 12, and they were higher than those in the lateral pharyngoplasty group except at hour 10; pain scores were significantly higher in the lateral pharyn- 24 6 Pain during swallowing pain at rest and during swallowing was less in the palatoplasty group. The success rates in our study-81.8% in the palatoplasty group and 82.6% in the flap group-were similar to those observed in previous studies.":" As mentioned, Pang and Terris reported a success rates of75.0%,14 and Pang et al reported a success rate of 71.8%15 in their studies of anterior palatoplasty.
In the previously mentioned comparison of anterior palatoplasty and uvulopalatal flap placement by Marzetti et al, the success rates with both procedures-86 and 84%, respectively-were very similar to ours." In that study, mean ESSvalues fell from 8.5 ± 3.7 preoperatively to 4.9 ± 3.2 postoperatively (p < 0.001) after anterior palatoplasty and from 8.1± 3.5 to 5.2 ± 3.2 after the flap procedure (p < 0.001),A satisfactory reduction in the volume of snoring on polysomnography data was achieved in both groups. In addition, responses to the Muller maneuver improved from 2.7 ± 1.0to 1.1 ± 0.9 (p < 0.001) after anterior palatoplasty and, to a lesser extent, from 2.8 ± 1.1 to 1.8 ± 1.1; P< 0.05) after the flap procedure. The mean duration of pain was 7.1 and 10.8 days, respectively; mean pain scores during the first 3 days were 5.1 and 6.8. The authors suggested that anterior palatoplasty was more practical and resulted in less discomfort than thef lap procedure.
In a study published in 2013,Uguretalcompared the long-term efficacy of anterior palatoplasty and modified uvulopalatopharyngoplasty (mUPPP) in 50 patients." The authors evaluated snoring
